1nl9 › Citations

Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy.

Szczepankiewicz BG, Liu G, Hajduk PJ, Abad-Zapatero C, Pei Z, Xin Z, Lubben TH, Trevillyan JM, Stashko MA, Ballaron SJ, Liang H, Huang F, Hutchins CW, Fesik SW, Jirousek MR
J Am Chem Soc 125 4087-96 (2003)
Related entries: 1nny, 1no6

Cited: 98 times
EuropePMC logo PMID: 12670229

Abstract

Protein tyrosine phosphatase 1B (PTP1B) is an enzyme that downregulates the insulin receptor. Inhibition of PTP1B is expected to improve insulin action, and the design of small molecule PTP1B inhibitors to treat type II diabetes has received considerable attention. In this work, NMR-based screening identified a nonselective competitive inhibitor of PTP1B. A second site ligand was also identified by NMR-based screening and then linked to the catalytic site ligand by rational design. X-ray data confirmed that the inhibitor bound with the catalytic site in the native, "open" conformation. The final compound displayed excellent potency and good selectivity over many other phosphatases. The modular approach to drug design described in this work should be applicable for the design of potent and selective inhibitors of other therapeutically relevant protein tyrosine phosphatases.

Reviews - 1nl9 mentioned but not cited (1)

  1. Human Protein Tyrosine Phosphatase 1B (PTP1B): From Structure to Clinical Inhibitor Perspectives. Liu R, Mathieu C, Berthelet J, Zhang W, Dupret JM, Rodrigues Lima F. Int J Mol Sci 23 7027 (2022)

Articles - 1nl9 mentioned but not cited (1)

  1. research-article Native dynamics and allosteric responses in PTP1B probed by high-resolution HDX-MS. Woods VA, Abzalimov RR, Keedy DA. bioRxiv 2023.07.12.548582 (2023)


Reviews citing this publication (21)

  1. Using chemical shift perturbation to characterise ligand binding. Williamson MP. Prog Nucl Magn Reson Spectrosc 73 1-16 (2013)
  2. A decade of fragment-based drug design: strategic advances and lessons learned. Hajduk PJ, Greer J. Nat Rev Drug Discov 6 211-219 (2007)
  3. Fragment-based lead discovery. Rees DC, Congreve M, Murray CW, Carr R. Nat Rev Drug Discov 3 660-672 (2004)
  4. PTP1B: from the sidelines to the front lines! Tonks NK. FEBS Lett 546 140-148 (2003)
  5. Inhibitors of protein tyrosine phosphatases: next-generation drugs? Bialy L, Waldmann H. Angew Chem Int Ed Engl 44 3814-3839 (2005)
  6. Perspectives on NMR in drug discovery: a technique comes of age. Pellecchia M, Bertini I, Cowburn D, Dalvit C, Giralt E, Jahnke W, James TL, Homans SW, Kessler H, Luchinat C, Meyer B, Oschkinat H, Peng J, Schwalbe H, Siegal G. Nat Rev Drug Discov 7 738-745 (2008)
  7. Fragment-based lead discovery: leads by design. Carr RA, Congreve M, Murray CW, Rees DC. Drug Discov Today 10 987-992 (2005)
  8. Protein tyrosine phosphatases: structure-function relationships. Tabernero L, Aricescu AR, Jones EY, Szedlacsek SE. FEBS J 275 867-882 (2008)
  9. Hit discovery and hit-to-lead approaches. Keseru GM, Makara GM. Drug Discov Today 11 741-748 (2006)
  10. Transforming fragments into candidates: small becomes big in medicinal chemistry. de Kloe GE, Bailey D, Leurs R, de Esch IJ. Drug Discov Today 14 630-646 (2009)
  11. Recent advances in protein tyrosine phosphatase 1B inhibitors. Taylor SD, Hill B. Expert Opin Investig Drugs 13 199-214 (2004)
  12. Biochemical applications of mass spectrometry in pharmaceutical drug discovery. Geoghegan KF, Kelly MA. Mass Spectrom Rev 24 347-366 (2005)
  13. NMR-based screening technologies. Coles M, Heller M, Kessler H. Drug Discov Today 8 803-810 (2003)
  14. Protein tyrosine phosphatase 1B inhibitors as antidiabetic agents - A brief review. Verma M, Gupta SJ, Chaudhary A, Garg VK. Bioorg Chem 70 267-283 (2017)
  15. Natural compounds as a source of protein tyrosine phosphatase inhibitors: application to the rational design of small-molecule derivatives. Ferreira CV, Justo GZ, Souza AC, Queiroz KC, Zambuzzi WF, Aoyama H, Peppelenbosch MP. Biochimie 88 1859-1873 (2006)
  16. Library screening by fragment-based docking. Huang D, Caflisch A. J Mol Recognit 23 183-193 (2010)
  17. Recent applications of protein crystallography and structure-guided drug design. Williams SP, Kuyper LF, Pearce KH. Curr Opin Chem Biol 9 371-380 (2005)
  18. Bidentate inhibitors of protein tyrosine phosphatases. Low JL, Chai CL, Yao SQ. Antioxid Redox Signal 20 2225-2250 (2014)
  19. Negishi cross-couplings in the synthesis of amino acids. Brittain WDG, Cobb SL. Org Biomol Chem 16 10-20 (2017)
  20. Phosphotyrosine isosteres: past, present and future. Cerulli RA, Kritzer JA. Org Biomol Chem 18 583-605 (2020)
  21. The development of protein tyrosine phosphatase1B inhibitors defined by binding sites in crystalline complexes. Zhang Y, Du Y. Future Med Chem 10 2345-2367 (2018)

Articles citing this publication (75)

  1. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD. Nature 535 148-152 (2016)
  2. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM. Nature 534 272-276 (2016)
  3. Ligand efficiency indices for effective drug discovery. Abad-Zapatero C. Expert Opin Drug Discov 2 469-488 (2007)
  4. Novel allosteric sites on Ras for lead generation. Grant BJ, Lukman S, Hocker HJ, Sayyah J, Brown JH, McCammon JA, Gorfe AA. PLoS One 6 e25711 (2011)
  5. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase. Frembgen-Kesner T, Elcock AH. J Mol Biol 359 202-214 (2006)
  6. Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Abad-Zapatero C, Perišić O, Wass J, Bento AP, Overington J, Al-Lazikani B, Johnson ME. Drug Discov Today 15 804-811 (2010)
  7. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. Davies DR, Mamat B, Magnusson OT, Christensen J, Haraldsson MH, Mishra R, Pease B, Hansen E, Singh J, Zembower D, Kim H, Kiselyov AS, Burgin AB, Gurney ME, Stewart LJ. J Med Chem 52 4694-4715 (2009)
  8. Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Zhao H, Liu G, Xin Z, Serby MD, Pei Z, Szczepankiewicz BG, Hajduk PJ, Abad-Zapatero C, Hutchins CW, Lubben TH, Ballaron SJ, Haasch DL, Kaszubska W, Rondinone CM, Trevillyan JM, Jirousek MR. Bioorg Med Chem Lett 14 5543-5546 (2004)
  9. A two stage click-based library of protein tyrosine phosphatase inhibitors. Xie J, Seto CT. Bioorg Med Chem 15 458-473 (2007)
  10. Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics. Ala PJ, Gonneville L, Hillman MC, Becker-Pasha M, Wei M, Reid BG, Klabe R, Yue EW, Wayland B, Douty B, Polam P, Wasserman Z, Bower M, Combs AP, Burn TC, Hollis GF, Wynn R. J Biol Chem 281 32784-32795 (2006)
  11. MAPK-specific tyrosine phosphatases: new targets for drug discovery? Barr AJ, Knapp S. Trends Pharmacol Sci 27 525-530 (2006)
  12. Protein pockets: inventory, shape, and comparison. Coleman RG, Sharp KA. J Chem Inf Model 50 589-603 (2010)
  13. Protein tyrosine phosphatase 1B and α-glucosidase inhibitory activities of Pueraria lobata root and its constituents. Seong SH, Roy A, Jung HA, Jung HJ, Choi JS. J Ethnopharmacol 194 706-716 (2016)
  14. Compound Design by Fragment-Linking. Ichihara O, Barker J, Law RJ, Whittaker M. Mol Inform 30 298-306 (2011)
  15. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera. Jung HA, Islam MN, Lee CM, Oh SH, Lee S, Jung JH, Choi JS. Chem Biol Interact 206 55-62 (2013)
  16. 3-Substituted indolizine-1-carbonitrile derivatives as phosphatase inhibitors. Weide T, Arve L, Prinz H, Waldmann H, Kessler H. Bioorg Med Chem Lett 16 59-63 (2006)
  17. Alpha,alpha-difluoro-beta-ketophosphonates as potent inhibitors of protein tyrosine phosphatase 1B. Li X, Bhandari A, Holmes CP, Szardenings AK. Bioorg Med Chem Lett 14 4301-4306 (2004)
  18. Methods of using click chemistry in the discovery of enzyme inhibitors. Srinivasan R, Li J, Ng SL, Kalesh KA, Yao SQ. Nat Protoc 2 2655-2664 (2007)
  19. Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: synthesis and structure-activity relationships of a peptide scaffold. Yue EW, Wayland B, Douty B, Crawley ML, McLaughlin E, Takvorian A, Wasserman Z, Bower MJ, Wei M, Li Y, Ala PJ, Gonneville L, Wynn R, Burn TC, Liu PC, Combs AP. Bioorg Med Chem 14 5833-5849 (2006)
  20. Promising Inhibitory Effects of Anthraquinones, Naphthopyrone, and Naphthalene Glycosides, from Cassia obtusifolia on α-Glucosidase and Human Protein Tyrosine Phosphatases 1B. Jung HA, Ali MY, Choi JS. Molecules 22 E28 (2016)
  21. α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitory Activity of Plastoquinones from Marine Brown Alga Sargassum serratifolium. Ali MY, Kim DH, Seong SH, Kim HR, Jung HA, Choi JS. Mar Drugs 15 (2017)
  22. Fragment screening by biochemical assay. Barker J, Courtney S, Hesterkamp T, Ullmann D, Whittaker M. Expert Opin Drug Discov 1 225-236 (2006)
  23. NMR-based screening: a powerful tool in fragment-based drug discovery. Klages J, Coles M, Kessler H. Analyst 132 693-705 (2007)
  24. Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors. Vazquez J, Tautz L, Ryan JJ, Vuori K, Mustelin T, Pellecchia M. J Med Chem 50 2137-2143 (2007)
  25. Structure-based optimization of benzoic acids as inhibitors of protein tyrosine phosphatase 1B and low molecular weight protein tyrosine phosphatase. Maccari R, Ottanà R, Ciurleo R, Paoli P, Manao G, Camici G, Laggner C, Langer T. ChemMedChem 4 957-962 (2009)
  26. A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway. Yang Z, Wu F, He Y, Zhang Q, Zhang Y, Zhou G, Yang H, Zhou P. Food Funct 9 397-406 (2018)
  27. Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors. Holmes CP, Li X, Pan Y, Xu C, Bhandari A, Moody CM, Miguel JA, Ferla SW, De Francisco MN, Frederick BT, Zhou S, Macher N, Jang L, Irvine JD, Grove JR. Bioorg Med Chem Lett 15 4336-4341 (2005)
  28. In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach. Rao GS, Ramachandran MV, Bajaj JS. J Biomol Struct Dyn 23 377-384 (2006)
  29. Probing acid replacements of thiophene PTP1B inhibitors. Wan ZK, Follows B, Kirincich S, Wilson D, Binnun E, Xu W, Joseph-McCarthy D, Wu J, Smith M, Zhang YL, Tam M, Erbe D, Tam S, Saiah E, Lee J. Bioorg Med Chem Lett 17 2913-2920 (2007)
  30. Druggability analysis and classification of protein tyrosine phosphatase active sites. Ghattas MA, Raslan N, Sadeq A, Al Sorkhy M, Atatreh N. Drug Des Devel Ther 10 3197-3209 (2016)
  31. Prunin is a highly potent flavonoid from Prunus davidiana stems that inhibits protein tyrosine phosphatase 1B and stimulates glucose uptake in insulin-resistant HepG2 cells. Jung HA, Ali MY, Bhakta HK, Min BS, Choi JS. Arch Pharm Res 40 37-48 (2017)
  32. Regioselective copper-catalyzed amination of chlorobenzoic acids: synthesis and solid-state structures of N-aryl anthranilic acid derivatives. Mei X, August AT, Wolf C. J Org Chem 71 142-149 (2006)
  33. Discovery of ligands for Nurr1 by combined use of NMR screening with different isotopic and spin-labeling strategies. Poppe L, Harvey TS, Mohr C, Zondlo J, Tegley CM, Nuanmanee O, Cheetham J. J Biomol Screen 12 301-311 (2007)
  34. Identification of Bidentate Salicylic Acid Inhibitors of PTP1B. Haftchenary S, Jouk AO, Aubry I, Lewis AM, Landry M, Ball DP, Shouksmith AE, Collins CV, Tremblay ML, Gunning PT. ACS Med Chem Lett 6 982-986 (2015)
  35. Investigations of linker structure on the potency of a series of bidentate protein tyrosine phosphatase inhibitors. Xie J, Seto CT. Bioorg Med Chem 13 2981-2991 (2005)
  36. Potent and selective inhibition of T-cell protein tyrosine phosphatase (TCPTP) by a dinuclear copper(II) complex. Yuan C, Zhu M, Wang Q, Lu L, Xing S, Fu X, Jiang Z, Zhang S, Li Z, Li Z, Zhu R, Ma L, Xu L. Chem Commun (Camb) 48 1153-1155 (2012)
  37. Computational analysis of tyrosine phosphatase inhibitor selectivity for the virulence factors YopH and SptP. Hu X, Vujanac M, Stebbins CE. J Mol Graph Model 23 175-187 (2004)
  38. Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B. Scior T, Mack HG, García JA, Koch W. Drug Des Devel Ther 2 221-231 (2009)
  39. Discovery and evaluation of the hybrid of bromophenol and saccharide as potent and selective protein tyrosine phosphatase 1B inhibitors. Zhang R, Yu R, Xu Q, Li X, Luo J, Jiang B, Wang L, Guo S, Wu N, Shi D. Eur J Med Chem 134 24-33 (2017)
  40. Discovery of orally active, potent, and selective benzotriazole-based PTP1B inhibitors. Patel D, Jain M, Shah SR, Bahekar R, Jadav P, Darji B, Siriki Y, Bandyopadhyay D, Joharapurkar A, Kshirsagar S, Patel H, Shaikh M, Sairam KV, Patel P. ChemMedChem 6 1011-1016 (2011)
  41. Exploring the chemical space around 8-mercaptoguanine as a route to new inhibitors of the folate biosynthesis enzyme HPPK. Chhabra S, Barlow N, Dolezal O, Hattarki MK, Newman J, Peat TS, Graham B, Swarbrick JD. PLoS One 8 e59535 (2013)
  42. Three-dimensional structure and ligand interactions of the low molecular weight protein tyrosine phosphatase from Campylobacter jejuni. Tolkatchev D, Shaykhutdinov R, Xu P, Plamondon J, Watson DC, Young NM, Ni F. Protein Sci 15 2381-2394 (2006)
  43. "Click" synthesis of small-molecule inhibitors targeting caspases. Ng SL, Yang PY, Chen KY, Srinivasan R, Yao SQ. Org Biomol Chem 6 844-847 (2008)
  44. Design and synthesis of paracaseolide A analogues as selective protein tyrosine phosphatase 1B inhibitors. Yin JP, Tang CL, Gao LX, Ma WP, Li JY, Li Y, Li J, Nan FJ. Org Biomol Chem 12 3441-3445 (2014)
  45. Discovery of novel, potent, selective and cellular active ADC type PTP1B inhibitors via fragment-docking-oriented de novel design. Du Y, Ling H, Zhang M, Shen J, Li Q. Bioorg Med Chem 23 4891-4898 (2015)
  46. Fragment-based synthesis and SAR of modified FKBP ligands: influence of different linking on binding affinity. Röhrig CH, Loch C, Guan JY, Siegal G, Overhand M. ChemMedChem 2 1054-1070 (2007)
  47. Illudalic acid as a potential LAR inhibitor: synthesis, SAR, and preliminary studies on the mechanism of action. Ling Q, Huang Y, Zhou Y, Cai Z, Xiong B, Zhang Y, Ma L, Wang X, Li X, Li J, Shen J. Bioorg Med Chem 16 7399-7409 (2008)
  48. Parallel synthesis of a library of bidentate protein tyrosine phosphatase inhibitors based on the alpha-ketoacid motif. Chen YT, Seto CT. Bioorg Med Chem 12 3289-3298 (2004)
  49. Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors. Dixit M, Tripathi BK, Srivastava AK, Goel A. Bioorg Med Chem Lett 15 3394-3397 (2005)
  50. A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors. Aronov AM, Bemis GW. Proteins 57 36-50 (2004)
  51. Limitations of the "tethering" strategy for the detection of a weak noncovalent interaction. Gasparini G, Martin M, Prins LJ, Scrimin P. Chem Commun (Camb) 1340-1342 (2007)
  52. Structural characterization and bioactivity evaluation of an acidic proteoglycan extract from Ganoderma lucidum fruiting bodies for PTP1B inhibition and anti-diabetes. Pan D, Wang L, Hu B, Zhou P. Biopolymers 101 613-623 (2014)
  53. Fucosterol activates the insulin signaling pathway in insulin resistant HepG2 cells via inhibiting PTP1B. Jung HA, Bhakta HK, Min BS, Choi JS. Arch Pharm Res 39 1454-1464 (2016)
  54. Structural basis for the modulation of CDK-dependent/independent activity of cyclin D1. Ferrer JL, Dupuy J, Borel F, Jacquamet L, Noel JP, Dulic V. Cell Cycle 5 2760-2768 (2006)
  55. Fragment-Based Drug Design Facilitated by Protein-Templated Click Chemistry: Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin. Mondal M, Unver MY, Pal A, Bakker M, Berrier SP, Hirsch AK. Chemistry 22 14826-14830 (2016)
  56. Inhibition Mechanism of Components Isolated from Morus alba Branches on Diabetes and Diabetic Complications via Experimental and Molecular Docking Analyses. Kwon RH, Thaku N, Timalsina B, Park SE, Choi JS, Jung HA. Antioxidants (Basel) 11 383 (2022)
  57. PTP1B inhibitors from Selaginella tamariscina (Beauv.) Spring and their kinetic properties and molecular docking simulation. Le DD, Nguyen DH, Zhao BT, Seong SH, Choi JS, Kim SK, Kim JA, Min BS, Woo MH. Bioorg Chem 72 273-281 (2017)
  58. Potent protein tyrosine phosphatase 1B (PTP1B) inhibiting constituents from Anoectochilus chapaensis and molecular docking studies. Cai J, Zhao L, Tao W. Pharm Biol 53 1030-1034 (2015)
  59. Rationalizing protein-ligand interactions for PTP1B inhibitors using computational methods. Ajmani S, Karanam S, Kulkarni SA. Chem Biol Drug Des 74 582-595 (2009)
  60. Design and synthesis of novel 1,2-dithiolan-4-yl benzoate derivatives as PTP1B inhibitors. Chen J, Gao LX, Gong JX, Jiang CS, Yao LG, Li JY, Li J, Xiao W, Guo YW. Bioorg Med Chem Lett 25 2211-2216 (2015)
  61. Inhibitors of the Yersinia protein tyrosine phosphatase through high throughput and virtual screening approaches. Hu X, Vujanac M, Southall N, Stebbins CE. Bioorg Med Chem Lett 23 1056-1062 (2013)
  62. α-Methyl artoflavanocoumarin from Juniperus chinensis exerts anti-diabetic effects by inhibiting PTP1B and activating the PI3K/Akt signaling pathway in insulin-resistant HepG2 cells. Jung HJ, Seong SH, Ali MY, Min BS, Jung HA, Choi JS. Arch Pharm Res 40 1403-1413 (2017)
  63. Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B. Scior T, Guevara-García JA, Melendez FJ, Abdallah HH, Do QT, Bernard P. Drug Des Devel Ther 4 231-242 (2010)
  64. Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. Ruddraraju KV, Aggarwal D, Niu C, Baker EA, Zhang RY, Wu L, Zhang ZY. J Med Chem 63 9212-9227 (2020)
  65. Insight into the PTP1B Inhibitory Activity of Arylbenzofurans: An In Vitro and In Silico Study. Shrestha S, Seong SH, Park SG, Min BS, Jung HA, Choi JS. Molecules 24 E2893 (2019)
  66. Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding sites. Kumar AP, Nguyen MN, Verma C, Lukman S. Proteins 86 301-321 (2018)
  67. Synthesis, In Vitro Evaluation and Molecular Docking of the 5-Acetyl-2-aryl-6-hydroxybenzo[b]furans against Multiple Targets Linked to Type 2 Diabetes. Mphahlele MJ, Choong YS, Maluleka MM, Gildenhuys S. Biomolecules 10 E418 (2020)
  68. Letter Discovery and Validation of the Binding Poses of Allosteric Fragment Hits to Protein Tyrosine Phosphatase 1b: From Molecular Dynamics Simulations to X-ray Crystallography. Greisman JB, Willmore L, Yeh CY, Giordanetto F, Shahamadtar S, Nisonoff H, Maragakis P, Shaw DE. J Chem Inf Model 63 2644-2650 (2023)
  69. Discovery of inhibitors targeting protein tyrosine phosphatase 1B using a combined virtual screening approach. Zhao D, Sun L, Zhong S. Mol Divers 26 2159-2174 (2022)
  70. PAIN-less identification and evaluation of small molecule inhibitors against protein tyrosine phosphatase 1B. Nasiri HR, Mracek P, Grimm SK, Gastaldello J, Kolodzik A, Ullmann D. Medchemcomm 8 1220-1224 (2017)
  71. Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors. Hong B, He J, Fan C, Tang C, Le Q, Bai K, Niu S, Xiao M. Mar Drugs 18 E526 (2020)
  72. 6-Formyl Umbelliferone, a Furanocoumarin from Angelica decursiva L., Inhibits Key Diabetes-Related Enzymes and Advanced Glycation End-Product Formation. Ali MY, Zamponi GW, Seong SH, Jung HA, Choi JS. Molecules 27 5720 (2022)
  73. Concise synthesis and PTP1B inhibitory activity of (R)- and (S)-dihydroresorcylide. Jiang CS, Zhang L, Gong JX, Li JY, Yao LG, Li J, Guo YW. J Asian Nat Prod Res 19 1204-1213 (2017)
  74. Identification and Optimization of Protein Tyrosine Phosphatase Inhibitors Via Fragment Ligation. Tiemann M, Rademann J. Methods Mol Biol 2743 239-270 (2024)
  75. NHC-Ni(II)-catalyzed cyclopropene-isocyanide [5 + 1] benzannulation. Huang JQ, Yu M, Yong X, Ho CY. Nat Commun 13 4145 (2022)


Quick links